BTMD biote Corp.
Data as of close
Healthcare · Medicinal Chemicals & Botanical Products
biote Corp. (BTMD) is a healthcare company in the Medicinal Chemicals & Botanical Products industry, with a market capitalization of $32 million. Shares last traded at $1.13, 61.8% below their 52-week high. Over the past year the stock is down 60.5%. BTMD trades at a price-to-earnings ratio of 5.53, below the Medicinal Chemicals & Botanical Products median of 11.94. Net profit margin is 3.2%, above the peer median of -8.8%. Revenue declined 2.5% year over year.
* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.
BTMD Dividend History
| Fiscal year end | Total dividends paid | Per share* | Payout ratio |
|---|---|---|---|
| 2025-12-31 | $2M | $0.05 | 6% |
| 2024-12-31 | $5M | $0.14 | 150% |
| 2023-12-31 | $9M | $0.34 | 262% |
| 2022-12-31 | $13M | $0.00 | — |
| 2021-12-31 | $11M | — | 103% |
*Per share derived as total dividends paid ÷ weighted diluted shares (SEC EDGAR/XBRL annual cash-flow facts). Reported history — not a forecast of future dividends.
Compare payers on the highest-dividend-yield screener.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q2 2026 | -$0.23 | 2026-08-07 |
| Q1 2026 | $0.06 | 2026-05-11 |
| Q4 2025 (derived) | $0.05 | 2026-03-13 |
| FY 2025 | $0.74 | 2026-03-13 |
| Q3 2025 | $0.22 | 2025-11-07 |
| Q2 2025 | $0.10 | 2025-08-08 |
Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.
Medicinal Chemicals & Botanical Products peers
BTMD vs 14 industry peers (Medicinal Chemicals & Botanical Products), by market cap. Data as of close
| DFTX | Definium Therapeutics, Inc. | $4.5B | — | — | — | +2.93% |
| RGC | Regencell Bioscience Holdings Ltd | $3.0B | — | — | — | -2.55% |
| TRLV | Trulieve Cannabis Corp. | $2.2B | — | 1.95 | -41.8% | +3.78% |
| CRON | Cronos Group | $1.2B | 17.82 | 6.96 | 39.1% | +1.04% |
| TLRY | Tilray Brands | $393M | — | 0.41 | -17.1% | +4.72% |
| SNDL | SNDL Inc. | $354M | — | — | — | +5.08% |
| CGC | Canopy Growth | $301M | — | 1.43 | -80.0% | +4.42% |
| ACB | Aurora Cannabis | $290M | — | — | — | +22.16% |
| USNA | USANA HEALTH SCIENCES INC | $275M | — | 0.30 | -2.4% | +1.16% |
| GLAS | Glass House Brands Inc. | $190M | — | 1.04 | -16.3% | -0.85% |
| NAGE | Niagen Bioscience, Inc. | $187M | 11.68 | 1.45 | 12.4% | -1.67% |
| MDWD | MediWound Ltd. | $173M | — | — | — | -0.52% |
| FTLF | FITLIFE BRANDS, INC. | $76M | 12.19 | 0.75 | 6.2% | -2.06% |
| BTMD | biote Corp. | $32M | 5.53 | 0.18 | 3.2% | -0.44% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.